Company

Revvity and BioMap Sign Strategic AI4S Partnership – A "Dry‑Wet" Closed‑Loop Alliance to Accelerate AI‑Empowered Life Sciences
BioMapRevvity

Revvity and BioMap Sign Strategic AI4S Partnership – A “Dry‑Wet” Closed‑Loop Alliance to Accelerate AI‑Empowered Life Sciences

Revvity and BioMap, Shanghai‑based biotechnology companies, announced that they have officially signed a strategic cooperation agreement centered on AI4S (AI for Science). The partnership will integrate artificial intelligence, biological computing,…

Lepu Medical's Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World's First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia

Lepu Medical’s Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World’s First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia

IASO Bio's In Vivo CAR‑T IASO208 Clears NMPA IND – CD20‑Targeting Therapy Heads to Phase Ib in the US for R/R B‑NHL

IASO Bio’s In Vivo CAR‑T IASO208 Clears NMPA IND – CD20‑Targeting Therapy Heads to Phase Ib in the US for R/R B‑NHL

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau
AmgenBeiGene

Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau

Shengwei Kunteng Raises RMB 200 Million in Series A Financing for POCT Development
FinanceShengwei Kunteng Biotechnology

Shengwei Kunteng Raises RMB 200 Million in Series A Financing for POCT Development

Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round
BiotechFinance

Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round

Aosaikang's Generic Livtencity Accepted for Review by China's NMPA
Aosaikang PharmaceuticalGeneric drugs

Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA

Show More